Oral anticoagulant therapy in a patient with CHA₂DS₂-VASc score 1
Terapia anticoagualante orale in paziente con CHA₂DS₂-VASc score 1
Keywords:Atrial fibrillation, Dabigatran, Risk, Stroke
Controlled studies of new oral anticoagulants (NOACs) in patients with atrial fibrillation have included above all patients at high risk of stroke, providing solid evidence on the benefits of anticoagulant therapy with such drugs in male patients with CHA2DS2-VASc score ≥2 and in women with a score of ≥3. Although estimates of stroke risk in patients with lower scores predominantly come from studies in patients not receiving NOAC, in many of these subjects anticoagulant therapy still seems able to provide clinical benefit. The current guidelines therefore recommend oral anticoagulant therapy in patients with CHA2DS2-VASc ≥1 in men and ≥2 in women. However, the use of this therapy must be carefully weighted with the expected reduction in the risk of stroke, the risk of bleeding and the patient's preferences. The paradygmatic case of a patient with CHA2DS2-VASc score 1 is reported in which acetylsalicylic acid therapy is substituted with dabigatran 150 mg / day in order to guarantee the patient maximum protection against the risk of stroke, without exposing him to an excessive risk of bleeding (Cardiology).
How to Cite
Copyright (c) 2018 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to AboutOpen agree to publish their articles under the Creative Commons NonCommercial 4.0 International License (CC BY-NC 4.0), which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.